Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled study of ALXN1850 in treatment-naive children with hypophosphatasia
MOH_2024-01-04_013161Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Dec 2023
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in hypophosphatasia (HPP) comparing ALXN1850 with Placebo (2 arms). Planned start Dec 2023; status: not yet recruiting.
02
Drugs
efzimfotase alfa
03
Conditions
hypophosphatasia (HPP)
Beyond the preview
Go deeper on MOH_2024-01-04_013161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-04_013161.